- Home
- AGIO
as of 03-06-2026 3:41pm EST
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.6B | IPO Year: | 2013 |
| Target Price: | $37.63 | AVG Volume (30 days): | 791.9K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.12 | EPS Growth: | -161.17 |
| 52 Week Low/High: | $22.24 - $46.00 | Next Earning Date: | 05-15-2026 |
| Revenue: | $43,011,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 75.68% | Revenue Growth (next year): | 167.63% |
| P/E Ratio: | -3.90 | Index: | N/A |
| Free Cash Flow: | -377293000.0 | FCF Growth: | N/A |
AI-Powered AGIO Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Agios Pharmaceuticals Inc. (AGIO)
Principal Accounting Officer
Avg Cost/Share
$28.88
Shares
5,272
Total Value
$152,255.36
Owned After
868
SEC Form 4
Principal Accounting Officer
Avg Cost/Share
$28.96
Shares
2,223
Total Value
$64,378.08
Owned After
868
Chief Medical Officer
Avg Cost/Share
$28.96
Shares
4,055
Total Value
$117,432.80
Owned After
74,406
Chief Executive Officer
Avg Cost/Share
$28.96
Shares
18,055
Total Value
$522,872.80
Owned After
164,548
Chief Legal Officer
Avg Cost/Share
$28.96
Shares
5,218
Total Value
$151,113.28
Owned After
44,086
Chief Commercial Officer
Avg Cost/Share
$28.96
Shares
2,868
Total Value
$83,057.28
Owned After
41,591
Chief Financial Officer
Avg Cost/Share
$28.96
Shares
5,035
Total Value
$145,813.60
Owned After
49,328
Chief Commercial Officer
Avg Cost/Share
$27.02
Shares
2,872
Total Value
$77,601.44
Owned After
41,591
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Mar 3, 2026 | Sell | $28.88 | 5,272 | $152,255.36 | 868 | |
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Mar 2, 2026 | Sell | $28.96 | 2,223 | $64,378.08 | 868 | |
| Gheuens Sarah | AGIO | Chief Medical Officer | Mar 2, 2026 | Sell | $28.96 | 4,055 | $117,432.80 | 74,406 | |
| Goff Brian | AGIO | Chief Executive Officer | Mar 2, 2026 | Sell | $28.96 | 18,055 | $522,872.80 | 164,548 | |
| Burns James William | AGIO | Chief Legal Officer | Mar 2, 2026 | Sell | $28.96 | 5,218 | $151,113.28 | 44,086 | |
| Milanova Tsveta | AGIO | Chief Commercial Officer | Mar 2, 2026 | Sell | $28.96 | 2,868 | $83,057.28 | 41,591 | |
| Jones Cecilia | AGIO | Chief Financial Officer | Mar 2, 2026 | Sell | $28.96 | 5,035 | $145,813.60 | 49,328 | |
| Milanova Tsveta | AGIO | Chief Commercial Officer | Jan 5, 2026 | Sell | $27.02 | 2,872 | $77,601.44 | 41,591 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 12, 2026 · 100% conf.
1D
+0.71%
$28.27
5D
+11.36%
$31.26
20D
+12.31%
$31.53
agio-202602120001439222FALSE00014392222026-02-122026-02-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026
Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
88 Sidney Street, Cambridge,MA 02139 (Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (617) 649-8600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, Par Value $0.001 per shareAGIONasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition.
On February 12, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter and year ended December 31, 2025 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description 99.1Press release issued February 12, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AGIOS PHARMACEUTICALS, INC.
Date: February 12, 2026 By: /s/ Brian Goff Brian Goff Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 30, 2025
Q3 2025 Earnings
8-KOct 30, 2025
agio-202510300001439222FALSE00014392222025-10-302025-10-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025
Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
88 Sidney Street, Cambridge,MA 02139 (Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (617) 649-8600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, Par Value $0.001 per shareAGIONasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition.
On October 30, 2025, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended September 30, 2025 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description 99.1Press release issued October 30, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AGIOS PHARMACEUTICALS, INC.
Date: October 30, 2025 By: /s/ Brian Goff Brian Goff Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Jul 31, 2025
Q2 2025 Earnings
8-KJul 31, 2025
agio-202507310001439222FALSE00014392222025-07-312025-07-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025
Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
88 Sidney Street, Cambridge,MA 02139 (Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (617) 649-8600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, Par Value $0.001 per shareAGIONasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition.
On July 31, 2025, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2025 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description 99.1Press release issued July 31, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AGIOS PHARMACEUTICALS, INC.
Date: July 31, 2025 By: /s/ Brian Goff Brian Goff Chief Executive Officer
Compare AGIO vs Leading Stocks
See how AGIO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AGIO Agios Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.